Cortendo AB to Present at the 13th Annual BIO Investor Forum in San Francisco October 7, 2014

October 3, 2014 -- Göteborg, Sweden and Radnor, Penn., U.S. -- Cortendo AB [ticker: CORT on NOTC-A], a biopharmaceutical company developing and commercializing products at the intersection of orphan diseases and endocrinology disorders, today announced that Matthew Pauls, President and CEO, will present at the 13th Annual BIO Investor Forum. The presentation is at the Palace Hotel in the Sea Cliff room on Oct. 7, 2014, at 3:00 p.m. PST in San Francisco, CA.

Pauls will present an update on the company and its lead asset, NormoCort (COR-003), which is being studied to treat Cushing’s syndrome in the international SONICS trial, a 90-patient, multi-site, open label Phase 3 study. The first patients enrolled in the SONICS trial in August.

The presentation will be available on the “Presentations” page in the Resources section of the company’s website at after the conference.

About Cortendo

Cortendo AB is a global biopharmaceutical company incorporated in Sweden and based in the United States. The Company’s strategic focus is to be the global leader in developing and commercializing products at the intersection of Orphan Diseases and Endocrinology Disorders. Cortendo aims to become the leader in the field of cortisol inhibition, with the lead drug candidate, NormoCort (COR-003), in a Phase 3 global clinical trial for the treatment of Cushing’s Syndrome. The company’s intent is to independently commercialize its Orphan/Endocrine assets in key global markets, and when necessary, partner non-strategic product opportunities, such as diabetes, at relevant development stages.

Risk and uncertainty

The development of pharmaceuticals carries significant risk. Failure may occur at any stage during development and commercialization due to safety or clinical efficacy issues. Delays may occur due to requirements from regulatory authorities, difficulties in recruiting patients into clinical trials due to physician or patient preferences or competing products, not anticipated by the company. There is no assurance that Cortendo will receive marketing and regulatory approvals necessary to commercialize or produce NormoCort (COR-003) or other products. Regulatory approvals may be denied, delayed, limited or revoked.

The commercial success of NormoCort (COR-003), if approved in a territory, cannot be predicted with certainty. In addition, Cortendo may face the risk of interrupted supply of NormoCort (COR-003) for clinical or commercial use from the subcontractors Cortendo has contracted.

Cortendo Forward-looking Statements

This press release contains forward-looking statements concerning Cortendo that involve a number of risks and uncertainties. All statements other than statements of historical facts included in this press release, including, without limitation, statements regarding the Company’s future financial position, strategy, anticipated investments, costs and results, plans, projects to enhance efficiency, outcomes of products development, future capital expenditures, liquidity requirements and objectives of management for future operations, may be deemed to be forward looking statements. These forward looking statements involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance or achievements or industry results to be materially different from those contemplated, projected, forecasted, estimated or budgeted, whether expressed or implied, by these forward looking statements. Given these risks and uncertainties, investors should not place any undue reliance on forward looking statements as a prediction of actual results. None of these forward looking statements constitutes a guarantee of the future occurrence of such facts and data or of actual results. These statements are based on data, assumptions and estimates that the Company believes are reasonable. The forward looking statements contained in this document are made only as of the date hereof. The Company expressly disclaims any obligation or undertaking to release publicly any updates of any forward-looking statements contained in this press release to reflect any change in its actual results, assumptions, expectations or any change in events, factors, conditions or circumstances on which any forward looking statement contained in this press release is based.

Investor and media contacts:

Alexander Lindström

Chief Financial Officer, Cortendo AB
Office : +1 610 254 9200
Mobile : +1 917 349 7210

E-mail : [email protected]

LaVoie Health Science
Donna LaVoie or Maureen Brown


[email protected]

[email protected]


Cortendo AB (publ)


Box 47

SE-433 21 Partille

Tel. / Fax. +46 (0)31-263010


555 East Lancaster Avenue

Suite 510

Radnor, PA 19087

Tel. +1 610-254-9200

Fax. +1 610-254-9245

© 2021 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Dublin Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
MLR-0010 V16 03/2020

  • Ireland Address:
    Suite 206, Fitzwilliam Hall
    Fitzwilliam Place, Dublin 2, D02 T292
  • U.S. Address:
    900 Northbrook Drive, Suite 200
    Trevose, PA 19053
    United States

Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program